Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27828136 | 0.86 | TSHR (0.41) | L3MBTL1ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL3769703 | 0.86 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL3770522 | 0.85 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL3776630 | 0.84 | CYP3A4 (0.46) | L3MBTL1ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL8651065 | 0.83 | HSD17B10 (0.51) | L3MBTL1ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL3778951 | 0.83 | ALDH1A1 (0.41) | ALDH1A1TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3773761 | 0.82 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL3767006 | 0.82 | LMNA (0.51) | L3MBTL1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL2842757 | 0.82 | DPP4 (0.45) | L3MBTL1ALDH1A1TSHRTDP1KMT2A | |
| SCHEMBL26288558 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TSHRKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851435-B2 | PTGR2 inhibitors and their use | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-12-26 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| EP-2163555-A1 | New pyrazole derivatives and diabetic medicine containing them | Ajinomoto Co., Inc. (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-1338603-B1 | NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME | AJINOMOTO KK (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-7645787-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2010-01-12 | — | — | US | disclosed |
| WO-2007014895-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014895-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
| US-7015201-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20060058244-A1 | New pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20050143424-A1 | Prophylactic and therapeutic agent of diabetes mellitus | AJINOMOTO CO. INC (JP) | 2005-06-30 | — | — | US | disclosed |
| US-20050043249-A1 | New pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1500403-A1 | PREVENTIVE/REMEDY FOR DIABETES | Ajinomoto Co., Inc. (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6815428-B2 | AS DIABETIC-MEDICINE WHICH IS EASY TO SYNTHESIZE, LESS TOXIC AND HAS HIGHER CURATIVE EFFECT | AJINOMOTO CO., INC. (JP) | 2004-11-09 | — | — | US | disclosed |
| US-20040006025-A1 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1338603-A1 | NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006025-A1 | Pyrazole derivatives and diabetic medicine containing them | SLC5A2, SLC5A1, DPP4 | L3MBTL1 4826/4885ALDH1A1 437/4885TSHR 2734/4885 |
| US-11851435-B2 | PTGR2 inhibitors and their use | PTGFR, PTGIR, PTGDR2 | L3MBTL1 4693/4885ALDH1A1 1177/4885TSHR 270/4885 |
| US-20060058244-A1 | New pyrazole derivatives and diabetic medicine containing them | DPP4, SLC5A2, SLC5A1 | L3MBTL1 4855/4885ALDH1A1 921/4885TSHR 2791/4885 |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | L3MBTL1 4855/4885ALDH1A1 921/4885TSHR 2791/4885 |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | PTGFR, PTGIR, PTGDR2 | L3MBTL1 4693/4885ALDH1A1 1177/4885TSHR 270/4885 |
| US-20050043249-A1 | New pyrazole derivatives and diabetic medicine containing them | DPP4, SLC5A2, SLC5A1 | L3MBTL1 4855/4885ALDH1A1 921/4885TSHR 2791/4885 |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | SLC5A1, SLC5A2, G6PC1 | L3MBTL1 4538/4885ALDH1A1 420/4885TSHR 4240/4885 |
| US-20050143424-A1 | Prophylactic and therapeutic agent of diabetes mellitus | SLC5A2, SLC5A1, GPR119 | L3MBTL1 3251/4885ALDH1A1 830/4885TSHR 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.